Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC.

J Alzheimers Dis. 2013;34(2):457-68. doi: 10.3233/JAD-122059.

PMID:
23234879
2.

Tau PET imaging in Alzheimer's disease.

Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y.

Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6. Review.

PMID:
25239654
3.

In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.

Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O'Brien JT.

Ageing Res Rev. 2017 Jul;36:50-63. doi: 10.1016/j.arr.2017.03.002. Epub 2017 Mar 15. Review.

PMID:
28315409
4.

Developments in Tau PET Imaging.

Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P.

Can J Neurol Sci. 2014 Sep;41(5):547-53. doi: 10.1017/cjn.2014.15. Review.

PMID:
25424608
5.

Imaging biomarkers in tauopathies.

Dani M, Edison P, Brooks DJ.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S26-8. doi: 10.1016/j.parkreldis.2015.08.011. Epub 2015 Aug 14. Review.

PMID:
26299160
6.

Novel PET/SPECT probes for imaging of tau in Alzheimer's disease.

Watanabe H, Ono M, Saji H.

ScientificWorldJournal. 2015;2015:124192. doi: 10.1155/2015/124192. Epub 2015 Mar 23. Review.

7.

Tau Positron Emission Tomography Imaging.

Kolb HC, Andrés JI.

Cold Spring Harb Perspect Biol. 2017 May 1;9(5). pii: a023721. doi: 10.1101/cshperspect.a023721. Review.

PMID:
27940517
8.

Advances in the development of tau PET radiotracers and their clinical applications.

Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y.

Ageing Res Rev. 2016 Sep;30:107-13. doi: 10.1016/j.arr.2015.12.010. Epub 2016 Jan 21. Review.

PMID:
26802556
9.

The merits of FDDNP-PET imaging in Alzheimer's disease.

Shin J, Kepe V, Barrio JR, Small GW.

J Alzheimers Dis. 2011;26 Suppl 3:135-45. doi: 10.3233/JAD-2011-0008. Review.

PMID:
21971458
10.

Characteristics of Tau and Its Ligands in PET Imaging.

Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y.

Biomolecules. 2016 Jan 6;6(1):7. doi: 10.3390/biom6010007. Review.

11.

Tau in Alzheimer disease and related tauopathies.

Iqbal K, Liu F, Gong CX, Grundke-Iqbal I.

Curr Alzheimer Res. 2010 Dec;7(8):656-64. Review.

12.
13.

Tau PET imaging: present and future directions.

Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A.

Mol Neurodegener. 2017 Feb 20;12(1):19. doi: 10.1186/s13024-017-0162-3. Review.

14.

Neurodegeneration and plasticity.

Arendt T.

Int J Dev Neurosci. 2004 Nov;22(7):507-14. Review.

PMID:
15465280
15.

Molecular imaging of dementia.

Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T.

Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Review.

16.

Molecular targets in the rational design of AD specific PET tracers: tau or amyloid aggregates?

Rojo LE, Gaspar PA, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):652-8. Review.

PMID:
21605040
17.

Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.

Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, Grundke-Iqbal I.

J Neural Transm Suppl. 1998;53:169-80. Review.

PMID:
9700655
18.

Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.

Brosch JR, Farlow MR, Risacher SL, Apostolova LG.

Neurotherapeutics. 2017 Jan;14(1):62-68. doi: 10.1007/s13311-016-0490-y. Review.

19.

Tau as a therapeutic target for Alzheimer's disease.

Boutajangout A, Sigurdsson EM, Krishnamurthy PK.

Curr Alzheimer Res. 2011 Sep;8(6):666-77. Review.

20.

18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features.

Furumoto S, Tago T, Harada R, Kudo Y, Okamura N.

Curr Alzheimer Res. 2017;14(2):178-185. Review.

PMID:
27334944

Supplemental Content

Support Center